Yorktown Management & Research CO Inc Neurocrine Biosciences Inc Transaction History
Yorktown Management & Research CO Inc
- $86.9 Million
- Q1 2025
A detailed history of Yorktown Management & Research CO Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Yorktown Management & Research CO Inc holds 2,850 shares of NBIX stock, worth $361,123. This represents 0.36% of its overall portfolio holdings.
Number of Shares
2,850
Previous 2,850
-0.0%
Holding current value
$361,123
Previous $389,000
19.02%
% of portfolio
0.36%
Previous 0.39%
Shares
3 transactions
Others Institutions Holding NBIX
# of Institutions
649Shares Held
97.6MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.8 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.26 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$701 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$616 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$338 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...